Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Please provide your email address to receive an email when new articles are posted on . The rise in discussion of ventilation support was due to two articles published in the June issue of CHEST being ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

The White House said Friday it’s adding three drugs for diabetes and lung disease to the self-pay platform TrumpRx, as the ...

Inhaled chronic obstructive pulmonary disease (COPD) medications prescribed before surgery in patients with early-stage non–small cell lung cancer (NSCLC) were associated with both short- and ...

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

Please provide your email address to receive an email when new articles are posted on . Less than 40% of the studied veteran cohort were adherent to their inhaled COPD medications. Adherence was found ...

“Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data from more recent years are ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...